Search

Your search keyword '"Wilcox, Maggie"' showing total 30 results

Search Constraints

Start Over You searched for: Author "Wilcox, Maggie" Remove constraint Author: "Wilcox, Maggie"
30 results on '"Wilcox, Maggie"'

Search Results

1. Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial

2. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

3. Management and 5-year outcomes in 9938 women with screen-detected ductal carcinoma in situ: the UK Sloane Project

4. Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies

5. Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution

6. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial

8. Addressing overtreatment of screen detected DCIS; the LORIS trial

9. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution

11. Six versus 12 months’ adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT

12. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

13. Fc effector function contributes to the activity of human anti-CTLA-4 antibodies

14. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

15. Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors

16. Fc-Optimized Anti-CD25 depletes tumor-infiltrating regulatory T Cells and synergizes with PD-1 Blockade to eradicate established tumors

17. Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor–Positive Early Breast Cancer: PALLET Trial

18. Risk factors for the development of invasive cancer in unresected ductal carcinoma in situ

20. Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution

21. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial

23. Tracking Genomic Cancer Evolution for Precision Medicine: The Lung TRACERx Study

24. Chemotherapy and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2–Negative (or unknown) Advanced Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline

25. Tracking Genomic Cancer Evolution for Precision Medicine: The Lung TRACERx Study

27. LETTERS.

29. Endocrine Therapy, New Biologicals, and New Study Designs for Presurgical Studies in Breast Cancer

Catalog

Books, media, physical & digital resources